Christoph Schöbel

Christoph Schöbel

Auto-generated profile, based on publicly available information

Christoph Schöbel

University Clinic Essen, West German Lung Centre, Ruhrlandklinik - Centre for Sleep and Telemedicine, Essen, Germany

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 May 2024 in Sleep and Breathing
Verified
Journal Article
Open access
PDF file
JGJonas Alexander Gross-Isselmann
Jonas Alexander Gross-Isselmann
TETorsten Eggert
Torsten Eggert
AWAlina Wildenauer
Alina Wildenauer
SDSarah Dietz-Terjung
Sarah Dietz-Terjung
MSMartina Grosse Sundrup
Martina Grosse Sundrup
CSChristoph Schoebel
Christoph Schoebel
Purpose: The cardiorespiratory polysomnography (PSG) is an expensive and limited resource. The Sleepiz One + is a novel radar-based contactless monitoring device that can be used e.g. for longitudinal detection of nocturnal respiratory events. The present study aimed to compare the performance of the Sleepiz One + device to the PSG regarding the accuracy of apnea–hypopnea index (AHI). Methods: From January to December 2021, a total of 141 adult volunteers who were either suspected of having sleep apnea or who were healthy sleepers took part in a sleep study. This examination served to validate the Sleepiz One + device in the presence and absence of additional SpO2 information. The AHI determined by the Sleepiz One + monitor was estimated automatically and compared with the AHI derived from manual PSG scoring. Results: The correlation between the Sleepiz-AHI and the PSG-AHI with and without additional SpO2 measurement was rp = 0.94 and rp = 0,87, respectively. In general, the Bland–Altman plots showed good agreement between the two methods of AHI measurement, though their deviations became larger with increasing sleep-disordered breathing. Sensitivity and specificity for recordings without additional SpO2 was 85% and 88%, respectively. Adding a SpO2 sensor increased the sensitivity to 88% and the specificity to 98%. Conclusion: The Sleepiz One + device is a valid diagnostic tool for patients with moderate to severe OSA. It can also be easily used in the home environment and is therefore beneficial for e.g. immobile and infectious patients. Trial registration number and date of registration for prospectively registered trials: This study was registered on clinicaltrials.gov (NCT04670848) on 2020–12-09.

Verified
Journal Article
Open access
PDF file
MWMathias Wollny
Mathias Wollny
CHClemens Heiser
Clemens Heiser
JSJ. Ulrich Sommer
J. Ulrich Sommer
CSChristoph Schöbel
Christoph Schöbel
MBMarcel Braun
Marcel Braun
Background/Objectives: Hypoglossal nerve stimulation (HNS) emerged as an alternative treatment for patients with obstructive sleep apnea (OSA) a decade ago. Long-term clinical trials and real-world data show that HNS treatment provides significant and sustained improvements in both OSA disease control and quality-of-life measures over time. Given the nature of HNS treatment, with the requirement of using an implantable neurostimulation system, patient safety is a critical domain in the assessment of this technology. The objective of this review was to evaluate adverse events (AEs) and complications with HNS therapy in a systematic review of published evidence. Methods: Medline, Cochrane, and Web of Science were systematically searched to identify randomized controlled and real-world observational studies reporting relevant outcomes with HNS therapy for treatment of OSA that included procedure-, device-, and treatment-related AEs. Results: Out of 418 articles screened, 27 were reviewed for eligibility, and 17 studies, the majority found to have low-to-moderate risk of bias, with data on 1962 patients were included for further analysis. Across included studies, reporting of AEs was heterogeneous with regard to the classifications used and the extent of reporting. Over an average follow-up duration of 17.5 ± 16.9 months, the pooled mortality rate was 0.01% (95% CI = 0.0 to 0.2%), with all reported deaths being unrelated to HNS treatment. The HNS system survival probability over the follow-up time of 60 months was 0.9834 (95% CI = 0.9768 to 0.9882), with infections and request for removal by patients being the most common indications. The pooled surgical revision rate was 0.08% (95% CI 0.0 to 0.2%). Most reported treatment-related side effects were transient stimulation-related discomfort (0.08%, 95% CI = 0.0 to 0.2%) and tongue abrasions (0.07%, 95% CI = 0.0 to 0.2%). Based on the systematic review, a standardized set of endpoints was defined, aiming to harmonize safety data relevant to HNS therapy. Conclusions: In this systematic review, HNS therapy for treatment of OSA is associated with a positive patient safety profile. AEs occur mainly at device implantation and during the treatment acclimatization period. Due to a lack of available evidence, partially implantable HNS systems are underrepresented in this review, which limits the generalizability of the results. Significant heterogeneity was found for adverse event reporting. A framework for reporting HNS outcomes that includes AEs and side effects is proposed to facilitate comparability of the reported data.

8 October 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MKMargarethe Konik
Margarethe Konik
MLMonika Lindemann
Monika Lindemann
MZMarkus Zettler
Markus Zettler
LMLara Kristina Meller
Lara Kristina Meller
Sebastian DolffSebastian Dolff
Sebastian Dolff
HRHana Rohn
Hana Rohn
The coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is currently the greatest medical challenge. Although crucial to the future management of the pandemic, the factors affecting the persistence of long-term SARS-CoV-2 immunity are not well understood. Therefore, we determined the extent of important correlates of SARS-CoV-2 specific protection in 200 unvaccinated convalescents after COVID-19. To investigate the effective memory response against the virus, SARS-CoV-2 specific T cell and humoral immunity (including virus-neutralizing antibodies) was determined over a period of one to eleven months. SARS-CoV-2 specific immune responses were present in 90% of individual patients. Notably, immunosuppressed patients did not have long-term SARS-CoV-2 specific T cell immunity. In our cohort, the severity of the initial illness influenced SARS-CoV-2 specific T cell immune responses and patients’ humoral immune responses to Spike (S) protein over the long-term, whereas the patients’ age influenced Membrane (M) protein-specific T cell responses. Thus, our study not only demonstrated the long-term persistence of SARS-CoV-2 specific immunity, it also determined COVID-19 severity and patient age as significant factors affecting long-term immunity.

17 February 2022 in Die Innere Medizin
Verified
Journal Article
Open access
PDF file
MBMarcel Braun
Marcel Braun
OSOlaf Schmidt
Olaf Schmidt
TSThomas Schultz
Thomas Schultz
HWHolger Woehrle
Holger Woehrle
MSMartina Große Sundrup
Martina Große Sundrup
CSChristoph Schöbel
Christoph Schöbel
Background Management of patients with respiratory disorders, such as asthma or chronic obstructive pulmonary disease (COPD), became challenging during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic due to infection prevention measures. To maintain care, a remote monitoring program was initiated, comprising a smartphone app and a Bluetooth spirometry device. Objective To assess patient- and physician-related experience with remote monitoring. Material and methods Structured questionnaires were developed to rate experiences from the patient or physician perspective on six-level Likert scales. Interactions between patients and physicians via the digital platform and overall utilization was analyzed. Results A total of 745 patients with asthma, COPD, post-coronavirus disease 2019 (COVID-19) and other respiratory diseases were enrolled from 31 centers in Germany. Mean follow-up was 49.4 +/- 12.6 weeks. Each participant submitted on average 289 measurements. Patient-reported experience with the remote monitoring program was positive, with the highest satisfaction reported for "Experience with home measurement" (1.4 +/- 0.5; 99% positive), followed by "Communication/interaction" (1.8 +/- 0.9; 83% positive) and "Overall satisfaction with program" (1.8 +/- 0.8; 87% positive). In all, 70% reported subjective quality of life improvements related to participation in the program. Physician satisfaction with the program was also high with a mean rating of 2.2 +/- 1.2. Discussion App-based remote monitoring was successfully implemented in routine care during the SARS-CoV-2 pandemic and demonstrated potential for improvements in care. Patient-relevant experience was positive in all dimensions and remote monitoring was well accepted. Physicians who participated in the program also expressed positive experiences, as demonstrated by a high level of interaction with the platform and positive evaluations of effects from the program.

1 June 2024 in Journal of Biomedical Optics
Verified
Journal Article
Open access
PDF file
WLWang Liao
Wang Liao
CZChen Zhang
Chen Zhang
BABelmin Alić
Belmin Alić
AWAlina Wildenauer
Alina Wildenauer
SDSarah Dietz-Terjung
Sarah Dietz-Terjung
GNGunther Notni
Gunther Notni
Vital signs, such as body temperature, heart rate, respiratory rate, and blood pressure are standard indicators of an individual’s physiological functions in most medical settings.1 Monitoring these vital parameters is crucial for early diagnosis, medical treatment, risk assessment, and patient recovery monitoring.2,3 With the advancement of medical measurement technology, oxygen saturation has increasingly become recognized as an indispensable fifth vital sign.4 Oxygen saturation indicates the percentage of oxygenated hemoglobin (HbO2) and hemoglobin (Hb) in the blood, in which the artery should be in the range of 95% to 100% in healthy individuals.5 Many pulmonary diseases cause abnormalities in oxygen saturation values, such as acute pneumonia, chronic obstructive pulmonary disease (COPD), and sleep apnea syndrome (SAS). Furthermore, the outbreak of coronavirus (COVID-19) has further underscored the critical importance of oxygen saturation measurement.

11 July 2024 in The Journal of Clinical Hypertension
Verified
Journal Article
Open access
AWAlina Wildenauer
Alina Wildenauer
LMLeonie Franziska Maurer
Leonie Franziska Maurer
LRLaurin Rötzer
Laurin Rötzer
TETorsten Eggert
Torsten Eggert
CSChristoph Schöbel
Christoph Schöbel
In this pilot study, the authors investigated the preliminary effectiveness of the digital lifestyle intervention, actensio (mementor DE GmbH), in treating arterial hypertension. Adults with arterial hypertension were randomly assigned to an intervention group (actensio + standard care) or a control group (waiting list + standard care) in a 1:1 ratio. Primary and secondary endpoints were assessed at baseline (t0) and 3 months post‐randomization (t1). The primary endpoint was average systolic blood pressure, measured at home for 1 week. Secondary endpoints included patient engagement (measured using the “patient activation measure”; PAM‐13), average diastolic blood pressure, and heart rate. All endpoints were analyzed using ANCOVA models, following an intention‐to‐treat approach, while adjusting for baseline values. Missing data were estimated using multiple imputation models. A total ofN = 102 participants (f = 59, age = 52.94 ± 9.01) were randomized to either the intervention (IG;N = 52) or the control group (CG;N = 50), of whichN = 80 completed the blood pressure diary, andN = 81 the PAM‐13 at t1. Between‐group comparisons showed an average group difference in systolic blood pressure of −5.06 mm Hg (95% CI = −8.71 to −1.41,p = .013) between the intervention group (M = 137.37 ± 10.13) and the control group (M = 142.35 ± 11.23). Average group difference for patient engagement was 3.35 points with a trend towards statistical significance (95% CI = −018 to 6.89,p = .064), favoring the intervention group (MIG = 79.38 ± 9.44 vs. MCG = 75.45 ± 10.62). There were no group differences in diastolic blood pressure (−1.78 mm Hg; 95% CI = −4.50 to 0.95,p = .402) and heart rate (−0.684; 95% CI = −3.73 to 2.36,p = 0.683). The results of the present pilot study confirm the preliminary effectiveness of the digital lifestyle intervention, actensio, in reducing high blood pressure in patients with hypertension.